Cost-Consequence Analysis of Three Different Diagnostic Strategies in the First- and Second-Line Treatment of Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. FE 2018, 19 (1). https://doi.org/10.7175/fe.v19i1.1354.